OBI-833

N/A

Report date: 2024/03/01 15:09:39

Base Information

Drug NameOBI-833
Drug Alias NameGlobo H-CRM-197OBI-833OBI-833/OBI-821
ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAcademia Sinica
China Registration ClassN/A

Develop Information

Active CompaniesOdeon Therapeutics lncNational Taiwan University HospitalChang Gung Memorial Hospital +[4] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungEsophageal NeoplasmsCholangiocarcinoma
Inactive IndicationsMetastatic breast cancerLung NeoplasmsStomach Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A